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SYNOPSIS 
 
Reprogramming of energetic metabolism is a phenotypic trait of cancer in which 
mitochondrial dysfunction represents a key event in tumor progression. Herein, we show that 
the acquisition of the tumor promoting phenotype in colon cancer HCT116 cells treated with 
oligomycin to inhibit the ATP synthase is exerted by repression of the synthesis of nuclear-
encoded mitochondrial proteins in a process that is regulated at the level of translation. 
Remarkably, the synthesis of glycolytic proteins is not affected in this situation. Changes in 
translational control of mitochondrial proteins are signaled by the activation of AMP-
activated protein kinase (AMPK) and the General Control nondepresible-2 (GCN2) kinase, 
leading also to the activation of autophagy. Changes in the bioenergetic function of 
mitochondria are mimicked by the activation of AMPK and the silencing of Activating 
Transcription Factor 4 (ATF4). These findings emphasize the relevance of translational 
control for normal mitochondrial function and for the progression of cancer. Moreover, 
demonstrate that glycolysis and oxidative phosphorylation are controlled at different levels of 
gene expression, offering to the cell a mechanistic safeguard strategy for metabolic 
adaptation under stressful conditions.  
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INTRODUCTION 
 
Mitochondria play a central role in the homeostasis of higher eukaryotic cells. The 
provision of metabolic energy by oxidative phosphorylation, the execution of cell death and 
intracellular signaling by Ca2+ and reactive oxygen species (ROS) are main cellular functions 
of the organelle. A growing number of human diseases, which include cancer, are associated 
with the molecular and/or functional alteration of mitochondria [1, 2]. The biogenesis of 
mitochondria is a complex genetic program that requires the concerted transcriptional 
response of nuclear and mitochondrial genes [3]. However, mechanisms that control the 
localization and translation of mRNAs also contribute to define the mitochondrial phenotype 
of the cell, offering the biogenesis of the H+-ATP synthase a paradigm in this regard [4]. 
Indeed, a master regulator in the provision of metabolic energy by oxidative phosphorylation 
is the mitochondrial H+-ATP synthase, a rotatory engine that utilizes the proton 
electrochemical gradient generated by the respiratory chain as a driving force for the 
phosphorylation of ADP [5].  
Cancer is a complex genetic disease in which the tumor microenvironment plays a 
fundamental role for disease progression [6, 7]. A hallmark of cancer cells and tumors is its 
peculiar energy metabolism [1, 8]. Carcinomas display increased glucose consumption rates 
due to a low activity of oxidative phosphorylation, concurrently showing higher rates of 
lactate production when compared to normal tissues [9]. It has been consistently reported that 
the relative expression of β-F1-ATPase1 (β catalytic subunit of the mitochondrial H+-ATP 
synthase), which is the catalytic subunit of the H+-ATP synthase, is significantly diminished 
in tumors when compared to its expression in normal tissues [1, 10]. In a large number of 
different carcinomas the down-regulation of β-F1-ATPase is accompanied by an increased 
expression of markers of the glycolytic pathway [1, 10]. This proteomic feature of cancer 
defines a “bioenergetic signature” of clinical relevance as an indicator of disease progression 
in colon, lung and breast cancer patients (for reviews see [1, 4]) as well as a predictive 
marker of the cellular response to chemotherapy [1, 11, 12]. Remarkably, recent findings 
have demonstrated that the activity of the H+-ATP synthase itself is inhibited in human 
carcinomas by up-regulation of its physiological inhibitor IF1, which is a relevant regulator 
of energetic metabolism in cancer cells [13]. The expression of β-F1-ATPase in developing 
liver [14, 15], brown adipose tissue [16], during progression through the cell cycle [17] and in 
rat [18] and human [19] carcinomas is exerted at the level of translation and largely mediated 
by the 3’UTR of the mRNA [14, 18, 19]. Similar findings have been obtained in yeast, where 
deletion of the 3’UTR leads to reduced ATP synthesis and respiratory dysfunction [20]. In 
addition, RNA binding proteins (RNABPs) of β-F1-ATPase mRNA (β-mRNA) have been 
shown to exert a relevant role in the control of translation of the mRNA both in development 
[14] and in carcinogenesis [18, 21].  
Down-regulation of β-F1-ATPase and the suppression of the bioenergetic activity of 
mitochondria is a required event to promote in vivo tumor progression in colon cancer [22]. 
In fact, we have recently demonstrated [22] that tumor xenografts derived from three isogenic 
HCT116 colon cancer cell lines differing in the expression level of β-F1-ATPase only 
develop when cells with the highly glycolytic phenotype are selected, i.e., tumor development 
requires the selection of cancer cells with a repressed biogenesis and functional activity of 
mitochondria. In other words, cancer cells with a functional activity of mitochondria are 
unable to develop tumors [22]. Importantly, such tumors displayed the transcriptomic, 
proteomic and mitochondrial ultrastructure of the cells treated with oligomycin [22]. These 
findings strongly emphasized the relevance of the cancer cell microenvironment for tumor 
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progression, further suggesting that cells treated with oligomycin (OL) [22] could provide a 
model to unveil the mechanisms involved in the acquisition of the malignant phenotype. In 
the present investigation we have addressed the mechanisms and signaling pathways that 
control the down-regulation of β-F1-ATPase in colon cancer cells treated with OL with the 
purpose of advancing in the knowledge of the phenotype that is competent for tumor 
promotion [22]. The results have uncovered that glycolysis and oxidative phosphorylation are 
regulated by different mechanisms of gene expression. Moreover, the results highlight the 
relevance of translational control mediated by the activation of the stress kinases AMPK [23] 
and GCN2 [24, 25] to specifically repress the translation of β-mRNA and the promotion of 
the abnormal bioenergetics of mitochondria in the cancer cell. Overall, we stress that the 
activation of AMPK and GCN2-ATF4 marks the onset of colon cancer progression. 
 
 
EXPERIMENTAL 
Cellular treatments and siRNA silencing. Human colorectal carcionoma HCT116 cells 
were grown at 37ºC and 7% CO2 in McCOY’s 5A media supplemented with 10% fetal 
bovine serum. Cells were left untreated (M-type cells) or treated with 6 μM OL for 48h (G-
type cells) [22]. Where indicated the cells were incubated with 0.1 mM AICAR for 48h. 
Transfections of AMPK plasmids [26] were carried out with Lipofectamine and Plus Reagent 
(Invitrogen). A plasmid encoding a mitochondrial version of green fluorescent protein was 
co-transfected with the plasmids of interest at a 1:10 ratio to assess transfeccion efficiencies. 
siRNA Quiagen s1702 used to suppress the expression of ATF4 was transfected using 
siPORT NeoFx reagent (Ambion/Applied Biosystems). An inefficient siRNA sequence, 
Silencer Select Negative Control number 1 plasmid (Ambion/Applied Biosystems), was used 
as a negative control and the siRNA of GAPDH was used as a positive control. The medium 
was changed at 24 h post-transfection and the cells were analyzed at 48h post-transfection for 
ATF4 expression.  
Western blots. Cellular pellets were resuspended in lysis buffer containing 25mM Hepes, 
2.5 mM EDTA, 1% Triton X-100, 1 mM PMSF and 5 μg/ml leupeptin. Extracts were 
centrifuged at 11,000g for 15 min at 4ºC. Protein concentration in the supernatants was 
determined with the Bradford reagent. Cellular proteins (7-20 μg) were fractionated on SDS- 
9% or SDS-15% PAGE and then transferred onto PVDF membranes. The primary antibodies 
used were: anti-β-F1-ATPase(1:50,000) [10], anti-Hsp60 (Stressgen SPA-807, 1:2,000),  
anti-GAPDH (1:20,000) and anti-PK (1:1,000) from Abcam, anti-SDH (1:500), anti-PDH 
(1:500) and anti-COX IV (1:250) from Invitrogen, anti-COX I (1:150) and anti-α-F1-ATPase 
(1:1,000) from Molecular Probe, anti-α-tubulin (1:5,000) and anti-LC3 (1:5,000) from Sigma, 
anti-β-catenin (BD Biosciences, 1:500), anti-GRK2 (1:500), anti-p53 (1:200), anti-HIF-1α 
(1:150), anti-PGC1α (1:250), anti-p70S6K (1:1,000), anti-HuR (1:200), anti-eIF2α (1:1,000) 
and anti-ATF4 (1:500) from Santa Cruz Biotechnology, anti-Akt (1:1,000), anti-p-Akt 
(1:1,000), anti-AMPK (1:1,000), anti-p-AMPK (1:1,000), anti p38 MAPK (1:1,000), anti-
mTOR (1:1,000), anti-p-mTOR (1: 1,000) anti-4EBP1 (1:1,000), anti-p-4EBP1 (1:1,000), 
anti-p-p70S6K (1:1,000), anti-p-eIF2α (1: 1,000) and anti-p-GCN2 (1:2,000), anti-p-raptor 
(1:1,000), anti-p-S6 (1:1,000), anti-p-ACC (1:1,000), anti-ULK1 Ser555 (1:1,000) and anti-
ULK1 Ser758 (1:1,000) from Cell Signaling, anti-GCN2 (1:2,000) [27], anti-c-Myc (1:400) 
from Roche Applied Science and anti-p62 (1:1,000) from Enzo Life Sciences. Secondary 
goat anti-rabbit, rabbit anti-goat and rabbit anti-mouse antibodies (1:5,000) were used for 
detection using a chemiluminescence detection method (ECL, Invitrogen). Membranes were 
exposed to X-ray films. Quantification of the immunoreactive bands (arbitrary units) was 
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accomplished using a Kodak DC120 Zoom digital camera and the Kodak 1D Image Analysis 
Software for Windows.  
Quantitative RT-PCR analysis. RNA samples were extracted from the cells using the 
RNAeasy mini kit (QIAGEN). Total RNA samples were quantified using a Nanodrop ND-
1000 spectrophotometer. RNA integrity was assessed with an Agilent 2100 Bioanalyzer. 
Reverse transcription (RT) reactions were performed using 1μg of total RNA and the High 
Capacity Reverse Transcription Kit (Applied Biosystems) with random primers. Primers 
were designed with Probe Finder Software (Roche Applied Science). The primers used were: 
β-F1-ATPase-F: cagcagattttggcaggtg, β-F1-ATPase-R: cttcaatgggtcccaccata; Hsp60-F: 
tgctatggctggagattttgt, Hsp60-R: cagcagcatccaataaagca; GAPDH-F: agccacatcgctcagacac, 
GAPDH-R: gcccaatacgaccaaatcc; G3BP1-F: ctttggtgggtttgtcactg, G3BP1-R: 
tgctgtctttcttcaggttcc; LC3-F: cgcaccttcgaacaaagag, LC3-R: ctcacccttgtatcgttctattatca; 18S-F: 
gcaattattccccatgaacg, 18S-R: gggacttaatcaacgcaagc; ATF4-F: tctccagcgacaaggctaa, ATF4-R: 
caatctgtcccggagaagg. Real-time PCR was performed using Power Sybr Green PCR Master 
Mix (Applied Biosystems) and LightCycler ® 2.0 Real-Time PCR System (Roche Applied 
Science). The relative expression of the mRNAs was determined using the comparative ΔΔCt 
method with GAPDH, G3BP1 GTPase (activating protein (SH3 domain) binding protein 1) 
or 18S (18S rRNA) as controls.  
Determination of mitochondrial DNA (mtDNA) copy number. Cellular DNA 
(nDNA+mtDNA) was extracted from the cells (4x105) using the High Pure PCR Template 
Preparation Kit from Roche. Quantification of mtDNA (mtDNA/nDNA) was performed by 
qPCR in the LightCycler ® 2.0 Real-Time PCR System (Roche Applied Science) using 5 ng 
of DNA, 0.5 μM of primers and the PCR reaction mixtures LightCycler® FastStart DNA 
MasterPLUS SYBR Green I (Roche Applied Science). The nuclear ATP5B and the 
mitochondrial 12S rRNA encoded genes were chosen to determine the ratio of mtDNA to 
nDNA. The primers used were: 12S-F: cccagggttggtcaatttc, 12S-R: ctttacgccggcttctattg; hβ-F: 
cagcagattttggcaggtg, hβ-R: cttcaatgggtcccaccata. The relative mtDNA copy number was 
calculated using the ΔΔCt method and the 12S/hβ ratio used to compare the samples.  
Metabolic Labeling and Immuno-precipitation. For pulse experiments, cells (~105) were 
incubated 20 min in cysteine-methionine-free medium. Metabolic labeling was initiated by 
addition of an aliquot of culture medium supplemented with 0.65 mCi of [35S]-
methionine/ml. After 30-45 min the radioactive medium was removed and the cells washed 
three times with PBS (phosphatebuffered saline) containing 5mM methionine and cysteine. 
Cellular pellets were resuspended in RIPA buffer (0.5M NaCl, 2% Triton X-100, 0.1M Tris-
HCl pH 8.0, 0.2% SDS, 1% Na-DOC) supplemented with protease inhibitor cocktail (Roche) 
and freeze-thawed three times. Protein concentration was determined with the Bradford 
reagent. The radioactivity incorporated into TCA precipitable protein was determined [15]. 
Immunoprecipitations were carried out from 100 μg protein of cellular extracts using G-
sepharose pre-coated with 6-7.5 μg of the IgGs of the following monoclonal antibodies: anti-
Hsp60 (clone 17/9-15 G1), anti-β-F1-ATPase (clone 11/21-7 A8), anti-PK (clone 1415-
21/24) or anti-GAPDH (clone 273A-E5) [28].  Pre-coating of G-sepharose was carried out 
overnight at 4ºC in 1 ml of RIPA buffer supplemented with 5 mg of BSA. After formation of 
the immune complexes, the resin was washed [21] and the immunoprecipitated material was 
resuspended in 1xSDS-PAGE sample buffer and loaded on a 9 % SDS-PAGE gel. Gels were 
further processed for fluorography and exposed to X-ray films. 
Determination of adenine nucleotides. Approximately, 107 cells were scraped off from 
the plates in PBS. Cells were precipitated and extracted with 500 μl of a 6% perchloric acid 
solution. After centrifugation at 15,000g to remove cell debris, the resulting supernatants 
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were neutralized with 2% KOH and freeze-dried. Determination of the cellular content of 
ATP, ADP and AMP was carried out by standard enzymatic procedures.  
Immunofluorescence microscopy. Cells were fixed with 4% paraformaldehyde for 20 
minutes and processed for immunofluorescence. The primary antibody used was rabbit anti-
LC3 antibody from Sigma (1:100). After three PBS rinses, the cells were incubated for 1h in 
the dark with anti-rabbit IgGs conjugated to Alexa-594 (1:1000). Cellular fluorescence was 
analyzed by confocal microscopy using a 63x1.4 oil plan-apocromate objective.  
Glycolysis and cellular respiration. Lactate concentrations in the culture media were 
enzymatically determined as an index of glycolysis [22]. Oxygen consumption rates were 
determined in a XF24 Extracellular Flux Analyzer (Seahorse Bioscience). Cells were seeded 
in the microplates, treated as indicated and incubated at 37ºC and 7% CO2 for 48h. The final 
concentration and order of injected substances was 6 μM OL, 0.75 mM 2,4-dinitrophenol 
(DNP), 1μM rotenone, and 1 μM antimycin [13].  
Statistical analysis. Statistical analyses were performed using a two-tailed Student’s t test. 
The results shown are the means±SEM. The number of experiments is indicated. A p < 0.05 
was considered statistically significant.  
 
 
RESULTS 
Oligomycin treatment represses the bioenergetic phenotype of mitochondria. 
Comparative transcriptomic analysis of HCT116 cells treated (G) or non-treated (M) with OL 
(oligomycin) suggested a global repression of the metabolic and bioenergetic function of 
mitochondria in G-cells [22]. The results in Fig. 1a indicate that G-cells have a diminished 
complement of pyruvate dehydrogenase (PDH-E1α), succinate dehydrogenase (SDH-A), 
subunits I (mtDNA encoded) and IV (nDNA encoded) of cytochrome c oxidase and of 
subunits α and β of the H+-ATP synthase when compared to non-treated M-cells. These 
changes occurred in the absence of relevant changes in the cellular content of the structural 
mitochondrial protein Hsp60 (heatshock protein 60) and in the abundance of the glycolytic 
markers GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and PK (pyruvate kinase) 
(Fig. 1a). Therefore, both the mitochondrion (β-F1/Hsp60 ratio) and overall mitochondrial 
potential of OL-treated cells as assessed by its bioenergetic signature (β-F1/GAPDH ratio) 
[4], were significantly diminished when compared to controls (Fig. 1b). Interestingly, these 
changes also occurred in the absence of relevant changes in mtDNA copy number (Fig. 1b). 
Consistent with the enzymatic phenotype displayed, G-cells had lower activity of oxidative 
phosphorylation (OSR in Fig. 1c) and an increased flux of lactate production (Fig. 1d).  
Inhibition of protein synthesis hampers the bioenergetic differentiation of mitochondria. 
Quantification by RT-qPCR of the cellular content of the mRNAs encoding β-F1-ATPase and 
GAPDH illustrated the lack of relevant differences in the abundance of these transcripts 
between M and G-cells (Fig. 2a). A slight but significant 15% reduction in Hsp60 mRNA 
levels was observed in G-cells (Fig. 2a) although this difference had no impact on protein 
expression (Fig. 1a). These findings indicate that down-regulation of -F1-ATPase in G-cells 
(Fig. 1a) could not be ascribed to a limited activity of the transcription of the ATP5B gene or 
to a regulatory event affecting the abundance of its mRNA. Rather, the results suggest that -
F1-ATPase expression is being controlled at the level of mRNA translation.  
To confirm this idea, we studied the initial rates of protein synthesis after a short time-
pulse of 35S-methionine in M- and G-cells. We observed no significant differences in the 
overall rate of protein synthesis between M- and G-cells (Fig. 2b). However, the results 
showed a significant 2-3 fold reduction in the relative rate of synthesis of β-F1-ATPase and 
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Hsp60, the two nuclear encoded mitochondrial proteins, in G-cells (Fig. 2b). In contrast, the 
relative rates of synthesis of the two glycolytic proteins were no different when compared to 
M-cells (Fig. 2b).  These findings indicate that the switch from the M- to the G-phenotype of 
colon cancer HCT116 cells [22] involves the specific repression of the translation of the 
mRNAs encoding mitochondrial proteins. In this regard, reanalysis of the transcriptomic 
study carried out to compare M and G cells [22] further indicated a highly significant 
(Benjamini P value=5,4E-5) repression of the expression of a large number of the 
mitochondrial aminoacyl-tRNA synthetases in G-cells. The lack of changes observed in 
Hsp60 expression in G cells (Fig. 1a) despite a significant reduction in its initial rate of 
synthesis (Fig. 2b) further suggests the participation of mechanisms operating at the level of 
protein turnover. 
Cellular adaptive response to OL treatment. Next, we monitored some of the relevant 
signaling pathways that are involved in the control of cell proliferation, survival and invasion 
and that might participate in the repression of the bioenergetic function of mitochondria. 
Interestingly, we found that HIF1α (hypoxia inducible factor 1 α) was not differentially 
expressed in G-cells when compared to M-cells (Fig. 3), consistent with the observation that 
OL blocks HIF1α expression [29]. Similar results were obtained for β-catenin, GRK2 (G 
protein-coupled receptor kinase 2), p38 MAPK (p38 mitogen-activated protein kinases) and 
both for the total and phosphorylated forms of the serine/threonine kinase Akt (v-akt murine 
thymoma viral oncogene) (Fig. 3). Notably, we found significant differences in the 
expression of the stress kinases AMPK and GCN2 supporting the activation of these 
pathways in cells with the G-phenotype (Fig. 3). Indeed, both the total and phosphorylated 
forms of AMPK were augmented in G- when compared to M-cells (Fig. 3). Consistent with 
the activation of AMPK we observed an increased cellular AMP/ATP ratio after short-term 
(2h) treatment of HCT116 cells with OL. Interestingly, the AMP/ATP ratio was not 
significantly different between M and G cells after 48h of treatment (Fig. 3). In the case of 
the GCN2 kinase, only the phosphorylated active form of the protein was augmented in cells 
with the G-phenotype (Fig. 3).  
Downstream targets of AMPK and GCN2. AMPK is a master protein kinase that regulates 
cell metabolism [23] and controls the activity of essential mediators of the cellular adaptive 
response such as p53 (tumor protein p53), HuR (ELAV-like protein) and the mammalian 
target of rapamycin (mTOR). Consistent with the activation of AMPK in G-cells we observed 
a large phosphorylation of raptor (Fig. 4) together with the down-regulation of the cellular 
content of mTOR and HuR in the absence of relevant changes in p53 when compared to M-
cells (Fig. 4). Interestingly, acetyl-CoA carboxylase (ACC), a well established target of 
AMPK that is phosphorylated and inhibited upon AMPK activation was not affected in G-
cells (Fig. 4), indicating the relevance that the synthesis of lipids has as pathway to allow 
cellular proliferation in colon cancer cells. The serine/threonine kinase mTOR controls 
translation and autophagy [30]. In agreement with the lesser signaling through mTOR we 
observe an increase in the total cellular content of the cap-dependent translation repressor 
4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [31] in G-cells (Fig. 4). 
The content of the phosphorylated form of 4EBP1 was also diminished in G-cells (Fig. 4) 
further supporting the sequestration of the rate limiting translation initiation factor 4E [32]. 
On the other hand, and to our surprise other downstream targets of mTOR such as p70S6K 
(ribosomal protein S6 kinase 70kDa polypeptide 1), its phosphorylated form (p-p70S6K) and 
that of its target the ribosomal protein S6 (p-S6) and of the transcription coactivator PGC1α 
(peroxisome proliferator-activated receptor gamma coactivator 1 α) revealed no-significant 
changes between both cellular phenotypes (Fig. 4). Likewise, and consistent with the 
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activation of GCN2 in G-cells (Fig. 3), we observed a significant increase in the cellular 
content of the transcription factor ATF4 when compared to M-cells (Fig. 4). It is well 
established that GCN2 represses translation via phosphorylation of eIF2α (eukaryotic 
translation initiation factor 2 α) and the subsequent up-regulation of the translation of ATF4. 
However, in our study both the content of eIF2α and of its phosphorylated form was 
significantly down-regulated (Fig. 4), what might suggest feedback inhibition of the 
phosphorylation of eIF2α after long-term (48 h) activation of GCN2. Overall, these results 
strongly suggest that a major point of regulation for promoting the repression of the 
bioenergetic function of mitochondria in G-cells is exerted at the level of translation by 
activation of the AMPK and GCN2 stress kinases.   
Autophagy is enhanced in G-cells. The phosphorylation of raptor (Fig. 4) and of Ser-555 
of the autophagy initiator kinase unc-51-like kinase 1 (ULK1) (Fig. 5a) suggested the 
AMPK-mediated inhibition of the mTOR signaling pathway and the subsequent activation of 
autophagy in cells with the G-phenotype [30]. Consistent with the mTOR-mediated activation 
of autophagy we also noted the dephosphorylation of Ser-758 of ULK1 in G-cells (Fig. 5a). 
Interestingly, a significant decrease in the cellular content of the p62 marker of autophagy 
was noted in G-cells (Fig. 5a). Gene expression analysis using the Affimetrix Platform also 
indicated the transcriptional activation of the autophagic LC3 (microtubule-associated protein 
1 light chain 3 α) gene (fold change increase of 1.7 in G-cells, p<0.009, [22]). Quantification 
of the expression of LC3 mRNA by RT-qPCR showed a significant increase in its cellular 
content in G-cells when compared to M-cells (Fig. 5b). Moreover, western blot data 
confirmed that the ratio of the conjugated form of LC3II to LC3I, which is a marker of 
autophagosome formation, is significantly increased in the G-phenotype (Fig. 5b). The higher 
abundance of autophagosomes in G-cells was further confirmed by immunofluorescence 
microscopy (Fig. 5c). Overall, these findings support that the activation of autophagy is an 
additional pro-survival strategy of the cancer cell to mediate the phenotypic changes that 
accompany the acquisition of the tumor promoting behavior in response to a bioenergetic 
stressor.  
AMPK activation and ATF4 mediate the inhibition of mitochondrial ATP synthesis. To 
assess the effect of the activation of the AMPK pathway in cellular bioenergetics we first 
determined the oxygen consumption rates of HCT116 cells (Fig. 6a). The results show a 
representative experiment of cellular O2 consumption after the sequential addition of OL, 
DNP (2,4-dinitrophenol), rotenone and antimycin to the cells, illustrating a normal respiratory 
response to the inhibition of oxidative phosphorylation (OL), mitochondrial uncoupling 
(DNP) and the inhibition of respiration in HCT116 cells. Moreover, data in Fig. 6b indicate 
the linear response of the maximum (MRR), basal (BRR) and oligomycin sensitive (OSR) 
respiratory rate of the cells at increasing numbers. The activation of AMPK pathway by 
treating the cells with 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR), an 
analog of AMP that is widely used as an activator of the pathway, promoted a significant 
decrease in OSR in HCT116 cells concurrently with the phosphorylation of AMPK (Fig. 6c). 
AICAR was used at a concentration of 0.1 mM because titration experiments of its effect on 
the proliferation of HCT116 cells indicated a high toxicity of the compound above this 
concentration (data not shown). Moreover, the expression of a constitutively active AMPK 
mutant (α1CA, T172D), which is a truncated version that is not dependent on regulatory 
subunits to activate the pathway [26] as revealed by the phosphorylation of AMPK (Fig. 6d) 
also promoted a large inhibition of oligomycin sensitive respiration when compared to their 
respective controls (Fig. 6d). These findings indicate that activation of AMPK partially 
hinders the activity of the mitochondrial ATP synthase. Interestingly, and consistent with our 
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previous observation of the lack of changes in p-ACC in G- when compared to M-cells (Fig. 
4), we show that the overexpression of α1CA (Fig. 6d) or AICAR treatment (Fig. 6c) does 
not affect the phosphorylation of ACC, stressing the relevance of lipogenesis for proliferation 
of HCT116 colon cancer cells.  
To confirm that activation of AMPK participates in controlling mitochondrial 
oxidative phosphorylation in colon cancer cells we next studied the effect of AICAR on the 
rates of β-F1-ATPase synthesis (Fig. 7). The results demonstrated that the activation of 
AMPK significantly reduced the initial rate of β-F1-ATPase synthesis in the absence of 
relevant changes on overall protein synthesis and on the synthesis of Hsp60, GAPDH and PK 
(Fig. 7), indicating that the activation of AMPK participates in the repression of the 
bioenergetic function of colon cancer mitochondria.   
To support the participation of the GCN2-ATF4 pathway in silencing the bioenergetic 
activity of mitochondria we determine the effect of silencing ATF4 in cellular respiration of 
M-cells (Fig. 8). The results obtained indicated that 40-60% silencing of ATF4 at both the 
mRNA and protein levels (Fig. 8a, b) resulted in a significant increase in oxidative 
phosphorylation (Fig. 8c) also supporting the participation of this pathway in promoting the 
repression of the bioenergetic activity of mitochondria in colon cancer.  
 
 
DISCUSSION 
We have recently documented that colon cancer progression requires the selection of 
cancer cells with a highly glycolytic phenotype due to the repression of the bioenergetic 
function of mitochondria [22]. However, the mechanisms and signaling pathways that trigger 
the down-regulation of β-F1-ATPase and hence of mitochondrial oxidative phosphorylation 
in colon cancer remained to be investigated. Colon cancer cells treated with oligomycin 
provide a model to decipher the mechanisms and signalling pathways that mediate the 
acquisition of the metabolic phenotype compatible with tumor progression [22, 33].  
The results in this work illustrate that metabolic stress triggered by OL-treatment to 
the cells promotes the persistent activation of the stress-kinases AMPK and GCN2 (Fig. 9). 
AMPK is a S/T kinase that regulates energetic metabolism and is activated under conditions 
that elevate the AMP/ATP ratio, such as glucose deprivation, hypoxia and muscle contraction 
[34]. AMPK activation triggers important changes in downstream targeted proteins with a 
wide functional relevance in homeostatic adaptation of the cell including the regulation of 
mitochondrial biogenesis [35] and function [36], autophagy [30] and angiogenesis [37]. 
Consistent with the activation of AMPK in G-cells we report the phosphorylation of raptor, a 
significant inhibition of mTOR, the subsequent inhibition of the synthesis of mitochondrial 
proteins and the activation of autophagy (Fig. 9). The up-regulation of the expression of 
genes involved in angiogenesis and vascular development has already been described in G-
cells [22]. GCN2 is also a stress kinase activated by nutrient deprivation and viral infection 
[24, 25] that represses the translation of most mRNAs but selectively increases translation of 
ATF4 [38]. Consistent with the activation of GCN2, we show that the content of ATF4 
transcription factor is significantly increased in G-cells (Fig. 9). It is likely that the 
coordinated activation of AMPK and GCN2 mediate the repression of the translation of 
nuclear-encoded mRNAs of mitochondria via 4EBP1 and eIF2α, respectively (Fig. 9). These 
changes trigger a profound switch in cellular energetic metabolism to an enhanced glycolysis 
due to a diminished activity of oxidative phosphorylation (Fig. 9). Remarkably, we report that 
whereas the synthesis and expression of nuclear-encoded mitochondrial proteins is stringently 
dependent on the activity of cap-dependent translation, that of the enzymes of glycolysis is 
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not affected by interference with this pathway suggesting the existence of a specific pathway 
for translation of the mRNAs involved in glycolysis. Due to the essential cellular function of 
glycolysis, it is possible that translation of glycolytic mRNAs shares signaling pathways and 
mechanisms with translation of the mRNAs involved in cellular adaptation to stressful 
condition [27]. These findings provide the first indication that the mechanisms that control 
the expression of the enzymes of the two main pathways of energy metabolism (OXPHOS 
and glycolysis) are exerted independently and at a different level of regulation of gene 
expression. In addition, it is likely that metabolic adaptation also involves the participation of 
additional mechanisms acting at the level of protein turnover. The repression of the 
bioenergetic function of mitochondria, which is a reversible phenotypic trait of the cancer cell 
[22], is thus orchestred by the activation of the stress sensors AMPK and GCN2. In 
agreement with our findings (Fig. 9), it has been recently described the activation of AMPK 
in colorectal [39] and ovarian [40] carcinomas and the requirement of the GCN2-ATF4 
pathway for maintaining metabolic homeostasis and tumor cell survival [38]. 
Interestingly, the repression of β-F1-ATPase expression observed in G-cells is not 
paralleled by changes in the cellular abundance of its mRNA. In fact, reduced β-F1-ATPase 
expression results from a translation masking event of β-mRNA in agreement with similar 
findings observed in human [19] and rat [18] carcinomas. It is tempting to suggest that the 
diminished expression of other mitochondrial proteins observed in G-cells (Fig. 1) could 
result by regulation of a common and presently unknown factor needed for translation of this 
particular set of nuclear-encoded mRNAs of mitochondria. Translation masking of β-mRNA 
during development [14] and in carcinogenesis [18, 21, 41] is due to the binding of specific 
RNABPs to the transcript. It has been suggested that regulated interactions within the 
ribonucleoprotein complex [42] hamper the efficient translation of β-mRNA [4]. Moreover, 
protein binding to β-mRNA was shown to depend on a low energy and oxidized state of the 
cell [43]. Consistent with these findings, it is possible that the increase in the AMP/ATP ratio 
observed at short term after treatment of the cells with OL could mediate the rapid silencing 
of β-mRNA by favoring the binding of repressor proteins onto the transcript (Fig. 9). In fact, 
AMPK activity has been correlated with the activity of some RNABPs such as HuR [44], a 
relevant RNABP involved in post-transcriptional regulation of gene expression that interacts 
with the 3’UTR of β-mRNA [41]. In agreement with recent findings [33], we observed that 
the activation of glycolysis in response to OL treatment provides enough ATP to recover a 
normal AMP/ATP ratio at long-term. Hence, it is likely that the persistent activation of 
AMPK observed in G-cells after 48h of OL-treatment is being mediated by additional 
regulators of the bioenergetically stressed cell.  
AMPK activation is related to an increased mitochondrial biogenesis in muscle and 
endothelial cells via transcriptional regulation mediated by PGC1α/NRF/Tfam pathway [3, 
35]. However, we do not observe changes in the expression of PGC1α in colon cancer 
stressed cells. In fact, our results indicate that the persistent activation of AMPK in stressed 
cells results in the repression of the bioenergetic differentiation of mitochondria by 
mechanisms controlled at the level of translation. This repression is most likely mediated via 
4EBP1 for transcripts encoded in nuclear genes and by a lower expression of the 
mitochondrial aminoacyl-tRNA synthetases for the transcripts encoded in mtDNA. A general 
belief is that the activation of AMPK and the inhibition of mTOR are cytotoxic to cancer 
cells [32, 45]. However, we observed that persistent activation of AMPK and the inhibition of 
mTOR are required to establish the tumor-promoting phenotype of colon cancer cells by 
repression of the bioenergetic function of mitochondria [22]. In this regard, and consistent 
with our observations, it has been described that the inhibition of the mTOR pathway down-
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regulates mitochondrial oxygen consumption and the ATP synthetic capacity [36]. In 
agreement with this, we show that AICAR treatment or the over-expression of a 
constitutively active mutant of AMPK, resulted in diminished ATP synthetic capacity and the 
inhibition of β-F1-ATPase synthesis. These findings strongly support that the activity of the 
mTOR pathway is essential for maintaining the bioenergetic function of mitochondria [36] 
and specifically of the synthesis of β-F1-ATPase. Within this frame, and in contrast to the 
beneficial effects of targeting mTOR in cancer [32, 45, 46], our results raise a reasonable 
argument against therapies targeting the activation of AMPK and the inhibition of mTOR for 
the treatment of colon cancer. In agreement with our observation, it has been described that 
the inhibition of AMPK sensitizes cancer cells to chemotherapy [47]. It is likely that these 
differences in cell response might stem from cell-type specific changes in the mechanisms 
that regulate the biogenesis and function of mitochondria [3].  
 AMPK and GCN2 are activated by stress signaling such as glucose deprivation, 
hypoxia, starvation of amino acids, etc [24, 25, 34]. Interestingly, none of these stimuli, 
including hypoxia, seem to operate in our model. However, it is remarkable that the energetic 
stress that activated AMPK in G-cells is very similar from the mechanistic point of view to 
the HIF–independent hypoxia-induced energy stress that activates mechanisms of energy 
conservation to promote survival under stressful conditions [48]. In this regard, we suggest 
that a product of mitochondrial metabolism such as reactive oxygen species (ROS) could act 
as signaling metabolite to maintain the cellular stress and the persistent activation of AMPK 
[49] and GCN2. The scenario where small molecules define the cellular energy status offer 
very attractive hypothesis to explain the mitochondrial phenotype and its short-term adaptive 
response upon changes in the metabolic condition of the cell. In this regard, we show that in 
response to energy stress the autophagic pathway is activated in G-cells perhaps as a strategy 
to eliminate the damaged proteins produced during adaptation to stress in order to optimize 
the limited energy supplies [30]. We show that the activation of the GCN2/eIF2α/ATF4 
pathway is involved in minimizing the bioenergetic function of mitochondria, allowing cells 
to conserve resources and the reconfiguration of gene expression to manage the energetic 
stress imposed, leading to the activation of glycolysis as alternative energy provision pathway 
(Fig. 9). In this regard, our results provide the first demonstration illustrating the implication 
of this pathway to control the stress-response when the mitochondrial bioenergetic function is 
impeded. Consistent with this, we show that the silencing of ATF4 restores the bioenergetic 
function of mitochondria. 
Overall, we conclude that persistent activation of AMPK and GCN2 regulate the 
balance between glycolysis and aerobic metabolism specifically repressing the translation of 
nuclear-encoded mitochondrial proteins. Activation of these signaling pathways is essential 
to implement a successful response that could allow cancer cells to survive under metabolic 
stress. Finally, our results open new insights in the pathways involved in the acquisition of a 
tumor promoter phenotype that implies a deregulated mitochondrial function, highlighting the 
importance that the organelle has as a tumor suppressor. 
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Figure legends  
 
 
 
Figure 1. Oligomycin treatment represses the bioenergetic function of mitochondria. 
HCT116 cells were incubated with oligomycin (OL) (closed bars, G) or left untreated (open bars, 
M) to promote changes in the bioenergetic phenotype. a, Representative western blots of the 
expression of PDH-E1α, SDH-A, COXI, COXIV, α-F1-ATPase, β-F1-ATPase, Hsp60, GAPDH, 
PK and tubulin in three different preparations (lanes 1-3) of M and G cells are shown. b, The 
mitochondrial (β-F1-ATPase/ Hsp60) and cellular (β-F1-ATPase/ GAPDH) normalized 
expression of β-F1-ATPase and the relative mtDNA copy number (12S/β-F1 ratio) are indicated. 
In a and b, the histograms show the quantification of the bands normalized to the mean value in 
control M-cells. c and d, The rates of OL-sensitive respiration and of lactate production were 
determined, respectively. The results shown are the mean ±SEM of at least three determinations. 
* P< 0.05 when compared to M-cells by Student’s t-test. The molecular mass of each protein is 
indicated on the left hand side of the blot. 
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Figure 2. Translational control hampers the bioenergetic function of mitochondria. 
HCT116 cells were incubated with OL (closed bars, G) or left untreated (open bars, M). a, 
Cellular RNA was extracted and the relative mRNA abundance of β-F1-ATPase (β-F1), Hsp60 
and GAPDH determined by qPCR. The results shown are the mean ±SEM of three experiments. 
b, Determination of the in vivo rate of β-F1, Hsp60, GAPDH and PK synthesis in M and G cells 
after metabolic labeling with 35S-methionine followed by immunoprecipitation (35S-IP). The 
radioactivity incorporated into TCA precipitable protein (Total) was determined. The histograms 
show the mean ±SEM of the quantification of the bands normalized to the mean value in control 
cells from three-six different preparations. p.i. non-specific immunoglobulin. * P< 0.05 when 
compared to M-cells by Student’s t-test. The molecular mass of each protein is indicated on the 
left hand side of the blot. 
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Figure 3.  Cellular adaptive response to energetic stress involves the activation of AMPK 
and GCN2. HCT116 cells were incubated with OL (closed bars, G) or left untreated (open bars, 
M). Representative western blots of the expression of HIF1α, β-catenin, GRK2, p38 MAPK, Akt, 
p-Akt, AMPK, p-AMPK, GCN2, p-GCN2 and tubulin in three different preparations (lanes 1-3) 
of M and G cells are shown. The histograms show the quantification of the bands normalized to 
the mean value in control M-cells. The results shown are the mean ±SEM of at least three 
determinations. The AMP/ATP ratio was determined in M-cells after 2h or 48h treatment with 
OL and normalized to the mean value in untreated cells. The results shown are the mean ±SEM 
of nine determinations. HCT116 cells incubated with 200 μM CoCl2 for 6h reveal the induction 
of HIF1α, a positive control to verify the specificity of the antibody used in the study. * P< 0.05 
and ** P<0.001 when compared to M or untreated cells by Student’s t-test. The molecular mass 
of each protein is indicated on the left hand side of the blot. 
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Figure 4. Energetic stress triggers significant changes in downstream targets of AMPK and 
GCN2. HCT116 cells were incubated with OL (closed bars, G) or left untreated (open bars, M). 
Representative western blots of the expression of p-raptor, mTOR, p-mTOR, 4EBP1, p-4EBP1, 
p70S6K, p-p70S6K, p-S6, HuR, p53, PGC1α, p-ACC, eIF2α, p-eIF2α, ATF4 and β-actin in three 
different preparations (lanes 1-3) of M and G cells are shown. The histograms show the 
quantification of the bands normalized to the mean value in control M-cells. The results shown 
are the mean ±SEM of three-nine determinations. * P< 0.05 and ** P<0.001 when compared to 
M cells by Student’s t-test.  
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Figure 5. Inhibition of mTOR triggers the activation of autophagy. HCT116 cells were 
incubated with OL (closed bars, G) or left untreated (open bars, M). a, Representative western 
blots of the expression of p-ULK1 in Ser555, p-ULK1 in Ser758 and p62 in three different 
preparations (lanes 1-3) of M and G cells are shown. The histograms show the quantification of 
the bands normalized to β-actin and to the mean value in control M-cells. The results shown are 
the mean ±SEM of three determinations. * P< 0.05 when compared to M cells by Student’s t-
test. b, Cellular mRNA was extracted and LC3 mRNA was determined by qPCR. The results 
shown are the mean ±SEM of three experiments. Analysis of LC3-I and its conjugated LC3-II 
form in four different preparations (lanes 1-4) of M and G cells by western blotting. The LC3-
II/LC3-I ratio was normalized to the mean value in control M-cells is represented in the 
histogram. The results shown are the mean ±SEM of four determinations. * P< 0.05 when 
compared to M-cells by Student’s t-test. c, Immunofluorescence microscopy of HCT116 cells 
incubated with OL for 48h (G, lower panels) or left untreated (M, upper panels), stained with 
anti-LC3 antibody. Images (x63) in G-cells illustrate the presence of autophagosomes (red 
cytoplasmic immunostaining). Bar, 10 μm.  The molecular mass of each protein is indicated on 
the left hand side of the blot. 
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Figure 6. AMPK activation promotes the inhibition of oxidative phosphorylation.  HCT116 
cells were seeded at various densities in Seahorse plates. a, Illustrates the oxygen consumption 
rates after the sequential addition of OL (a), DNP (b), rotenone (c) and antimycin (d) to the cells. 
b, The plot show the linear response of the basal (BCR), OL-sensitive (OSR) and maximum 
(DNP-induced, MRR) respiratory rates at various cell densities. c, Incubation of M-cells with 0.1 
mM AICAR promoted a significant decrease in OSR (closed bars) when compared with 
untreated (open bars) cells. The results shown are the mean ±SEM of three experiments. 
Representative western blots of the expression of p-AMPK and p-ACC are shown. d, Expression 
of a constitutively active AMPK mutant (α1CA), as revealed by western blot with either anti-
Myc-tag or anti-AMPK, promotes a large inhibition of OSR (closed bars) when compared to 
control GFP transfected cells (open bars). The results shown are the mean ±SEM of three 
experiments. * P< 0.05 when compared to control cells by Student’s t-test. Representative 
western blots of the expression of p-AMPK and p-ACC are shown. The molecular mass of each 
protein is indicated on the left hand side of the blot. 
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Figure 7. AMPK activation inhibits β-F1-ATPase synthesis. HCT116 cells were incubated 
with 0.1mM AICAR (closed bars) or left untreated (open bars). Determination of the in vivo rate 
of β-F1, Hsp60, GAPDH and PK synthesis in AICAR treated and untreated cells after metabolic 
labeling with 35S-methionine followed by immunoprecipitation (35S-IP). The radioactivity 
incorporated into TCA precipitable protein (Total) was determined. The histograms show the 
mean ±SEM of the quantification of the bands normalized to the mean value in control cells from 
three different preparations (lanes 1-3). p.i. non-specific immunoglobulin. * P< 0.05 when 
compared to untreated cells by Student’s t-test. The molecular mass of each protein is indicated 
on the left hand side of the blot. 
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Figure 8. Silencing of ATF4 promotes the bioenergetic function of mitochondria. a, Cellular 
lysates of control (c), GAPDH-silenced (siGAPDH, also used as control, c) and ATF4-silenced 
(siATF4) cells were analyzed by western blotting for the expression of β-F1-ATPase (β-F1), 
Hsp60, GAPDH and ATF4.  The histograms show the quantification of the bands normalized to 
the mean value in control cells. b, Cellular mRNA was extracted from control and ATF4-
silenced cells and ATF4 mRNA determined by qPCR. c, Silencing of ATF4 mediates a large 
increase in OL-sensitive (OSR) respiratory rate when compared to control cells. The results 
shown are the mean ±SEM of three (b) or five (c) experiments.* P< 0.05 when compared to 
control cells by Student’s t-test. The molecular mass of each protein is indicated on the left hand 
side of the blot. 
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Figure 9. Schematic diagram illustrating the major signaling pathways and mediators 
involved in the acquisition of the tumor-promoting phenotype in colon cancer cells. 
Energetic stress triggered by the inhibition of oxidative phosphorylation with oligomycin 
promotes short-term changes in the AMP/ATP ratio and in the rates of glycolysis. Moreover, 
OL-treatment promotes the persistent activation of the AMPK and GCN2 pathways. Activation 
of AMPK, phosphorylates raptor and represses mTOR and HuR expression with further 
consequences in the augmented expression of 4EBP1 and the induction of autophagy. The 
activation of GCN2 cooperates with AMPK in down-regulating cap-dependent translation via 
eIF2α. Overall, all these changes impact at short or long-term on the synthesis of mitochondrial 
proteins, specifically on β-F1-ATPase synthesis. As a consequence, mitochondrial activity is 
repressed, enhancing glycolysis and the acquisition of the tumor-promoting phenotype of colon 
cancer cells.  
 
 
 
 
 
